Literature DB >> 19168589

Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China.

Sue K Park1, Gabriella Andreotti, Lori C Sakoda, Yu-Tang Gao, Asif Rashid, Jinbo Chen, Bingshu E Chen, Philip S Rosenberg, Ming-Chang Shen, Bing-Sheng Wang, Tian-Quan Han, Bai-He Zhang, Meredith Yeager, Stephen Chanock, Ann W Hsing.   

Abstract

Biliary tract cancers, encompassing gallbladder, extrahepatic bile duct and ampulla of Vater cancers, are uncommon but often fatal malignancies. Hormone-related factors, including parity, oral contraceptive use, obesity, and gallstones, have been implicated in the etiology of these cancers. To further clarify the role of hormones in biliary tract cancers and biliary stones, we genotyped 18 single-nucleotide polymorphisms (SNPs) in nine genes involved in steroid hormone biosynthesis, metabolism and transport in a population-based case-control study in Shanghai, China. This study included subjects who completed an interview and provided blood, which totaled 411 biliary tract cancer and 893 biliary stone patients and 786 healthy Shanghai residents. The CYP1A1 IVS1 + 606 (rs2606345) T allele was associated with gallbladder [odds ratio (OR) = 2.0, 95% confidence interval (CI), 1.3-3.0] and bile duct cancers (OR = 1.8, 95% CI = 1.1-3.1), whereas the CYP1A1 Ex7 + 131 (rs1048943) G allele was associated with ampulla of Vater cancer (OR = 2.9, 95% CI = 1.5-5.4). After taking into account multiple comparisons for SNPs within each gene, CYP1A1 was significantly associated with gallbladder (P = 0.004) and ampulla of Vater cancers (P = 0.01), but borderline with bile duct cancer (P = 0.06). The effect of CYP1A1 IVS1 + 606 on gallbladder cancer was more pronounced among non-obese (body mass index < 23) (OR = 3.3, 95% CI = 1.8-6.1; P interaction = 0.001). Among women taking oral contraceptives, the effect of SHBG Ex8 + 6 (rs6259) on gallbladder cancer (OR = 6.7, 95% CI = 2.2-20.5; P interaction = 0.001) and stones (OR = 2.3, 95% CI = 1.1-4.9; P-interaction = 0.05) was statistically significant. Our findings suggest that common variants in hormone-related genes contribute to the risk of biliary tract cancers and stones, possibly by modulating hormone metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168589      PMCID: PMC2664453          DOI: 10.1093/carcin/bgp024

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  43 in total

Review 1.  Estrogen replacement therapy and gallbladder disease in postmenopausal women.

Authors:  M L Uhler; J W Marks; H L Judd
Journal:  Menopause       Date:  2000 May-Jun       Impact factor: 2.953

2.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

3.  Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies.

Authors:  Esteve Fernandez; Silvano Gallus; Cristina Bosetti; Silvia Franceschi; Eva Negri; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2003-06-20       Impact factor: 7.396

4.  Post-menopausal hormonal therapy and gallbladder cancer risk.

Authors:  Silvano Gallus; Eva Negri; Liliane Chatenoud; Cristina Bosetti; Silvia Franceschi; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

5.  Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity.

Authors:  D Schwarz; P Kisselev; W H Schunck; A Chernogolov; W Boidol; I Cascorbi; I Roots
Journal:  Pharmacogenetics       Date:  2000-08

6.  Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study.

Authors:  J A Simon; D B Hunninghake; S K Agarwal; F Lin; J A Cauley; C C Ireland; J H Pickar
Journal:  Ann Intern Med       Date:  2001-10-02       Impact factor: 25.391

Review 7.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.

Authors:  H Bartsch; U Nair; A Risch; M Rojas; H Wikman; K Alexandrov
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

Review 8.  Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans.

Authors:  Amrita Kamat; Margaret M Hinshelwood; Barbara A Murry; Carole R Mendelson
Journal:  Trends Endocrinol Metab       Date:  2002-04       Impact factor: 12.015

9.  Genetic polymorphisms of cytochrome P450 1A1 and risk of gallbladder cancer.

Authors:  Y Tsuchiya; T Sato; C Kiyohara; K Yoshida; K Ogoshi; K Nakamura; M Yamamoto
Journal:  J Exp Clin Cancer Res       Date:  2002-03

Review 10.  Adrenal and gonadal function in obesity.

Authors:  R Pasquali; V Vicennati; A Gambineri
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

View more
  15 in total

1.  Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma.

Authors:  Ling-Qiang Zhang; Xin-Sen Xu; Yong Wan; Si-Dong Song; Rui-Tao Wang; Wei Chen; Zhi-Xin Wang; Hu-Lin Chang; Ji-Chao Wei; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  DNMT3B -579 G>T promoter polymorphism and risk of gallbladder carcinoma in North Indian population.

Authors:  Kshitij Srivastava; Anvesha Srivastava; Balraj Mittal
Journal:  J Gastrointest Cancer       Date:  2010-12

Review 3.  Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis.

Authors:  Kshitij Srivastava; Anvesha Srivastava; Kiran Lata Sharma; Balraj Mittal
Journal:  Mutat Res       Date:  2011-06-25       Impact factor: 2.433

4.  Androgen receptor CAG repeat length and risk of biliary tract cancer and stones.

Authors:  Tamra E Meyer; Thomas G O'Brien; Gabriella Andreotti; Kai Yu; Qizhai Li; Yu-Tang Gao; Asif Rashid; Ming-Chang Shen; Bing-Sheng Wang; Tian-Quan Han; Bai-He Zhang; Shelley Niwa; Joseph F Fraumeni; Ann W Hsing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

Review 5.  Pathology of gallbladder carcinoma: current understanding and new perspectives.

Authors:  Munita Meenu Bal; Mukta Ramadwar; Kedar Deodhar; Shailesh Shrikhande
Journal:  Pathol Oncol Res       Date:  2015-01-25       Impact factor: 3.201

Review 6.  Modern perspectives on factors predisposing to the development of gallbladder cancer.

Authors:  Charles H C Pilgrim; Ryan T Groeschl; Kathleen K Christians; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2013-01-18       Impact factor: 3.647

7.  Association of genetic variants of xenobiotic and estrogen metabolism pathway (CYP1A1 and CYP1B1) with gallbladder cancer susceptibility.

Authors:  Kiran Lata Sharma; Akash Agarwal; Sanjeev Misra; Ashok Kumar; Vijay Kumar; Balraj Mittal
Journal:  Tumour Biol       Date:  2014-02-18

8.  Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy.

Authors:  Anshika Srivastava; Kiran Lata Sharma; Neena Srivastava; Sanjeev Misra; Balraj Mittal
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

9.  Molecular characterization of gallbladder cancer using somatic mutation profiling.

Authors:  Milind Javle; Asif Rashid; Chaitanya Churi; Siddhartha Kar; Mingxin Zuo; Agda Karina Eterovic; Graciela M Nogueras-Gonzalez; Filip Janku; Rachna T Shroff; Thomas A Aloia; Jean-Nicholas Vauthey; Steven Curley; Gordon Mills; Ivan Roa
Journal:  Hum Pathol       Date:  2013-11-12       Impact factor: 3.466

10.  Multi-analytic approach elucidates significant role of hormonal and hepatocanalicular transporter genetic variants in gallstone disease in North Indian population.

Authors:  Anshika Srivastava; Avshesh Mishra; Rajan Singh; Rajani Rai; Neena Srivastava; Balraj Mittal
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.